Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Tables)

v3.22.1
Organization and Nature of Operations (Tables)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedule of company's subsidiaries consolidated financial statements
Name of Subsidiary   Place and date of Incorporation   Percentage of Ownership   Principal Activities
Avalon Healthcare System, Inc.
(“AHS”)
  Delaware
May 18, 2015
  100% held by AVCO   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)
             
Avalon (BVI) Ltd.
(“Avalon BVI”)
  British Virgin Island
January 23, 2017
  100% held by AVCO   Dormant, is in process of being dissolved
             
Avalon RT 9 Properties LLC
(“Avalon RT 9”)
  New Jersey
February 7, 2017
  100% held by AVCO   Owns and operates an income-producing real property and holds and manages the corporate headquarters
             
Avalon (Shanghai) Healthcare Technology Co., Ltd.
(“Avalon Shanghai”)
  PRC
April 29, 2016
  100% held by AHS   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in China
             
Genexosome Technologies Inc.
(“Genexosome”)
  Nevada
July 31, 2017
  60% held by AVCO   Dormant
             
Beijing Jieteng (Genexosome) Biotech Co., Ltd.
(“Beijing Genexosome”)
  PRC
August 7, 2015
  100% held by Genexosome   Dormant
             
Avactis Biosciences Inc.
(“Avactis”)
  Nevada
July 18, 2018
  100% held by AVCO   Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers
             
International Exosome Association LLC
(“Exosome”)
  Delaware
June 13, 2019
  100% held by AVCO   Promotes standardization related to exosome industry